Cargando…

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

AIMS: Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic proprotein convertase subtilisi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray, Kausik K, Kallend, David, Leiter, Lawrence A, Raal, Frederick J, Koenig, Wolfgang, Jaros, Mark J, Schwartz, Gregory G, Landmesser, Ulf, Garcia Conde, Lorena, Wright, R Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769955/ https://www.ncbi.nlm.nih.gov/pubmed/36331315 http://dx.doi.org/10.1093/eurheartj/ehac615

Ejemplares similares

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023)

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
por: Cupido, Arjen J, et al.
Publicado: (2020)

Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022)

Orion
por: Glass, Philip, et al.
Publicado: (2005)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
por: Kallend, David, et al.
Publicado: (2022)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
por: Lehoux, Dario, et al.
Publicado: (2023)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

International Workshop on the Orion Complex Revisited
por: McCaughrean, M J, et al.
Publicado: (1997)

ORION: An Advanced Accelerator Facility at SLAC
por: Palmer, D T, et al.
Publicado: (2001)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
por: Arnold, Natalie, et al.
Publicado: (2022)

Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023)

SolarWinds Orion network performance monitor
por: Dissmeyer, Joe
Publicado: (2013)

ORION-the Omega Remote Interactive On-line System
por: Russell, R D, et al.
Publicado: (1974)

ORION - the OMEGA Remote Interactive On-line System
por: Russell, R D, et al.
Publicado: (1973)

Dataset of experimental measurements for the Orion beam structure()
por: Teloli, Rafael de Oliveira, et al.
Publicado: (2021)

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
por: Makhmudova, U., et al.
Publicado: (2023)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Giant star in orion may turn into a supernova
por: Browne, M W
Publicado: (1998)

The Orion Project Workshop : an Advanced Accelerator Research Facility
por: Collective
Publicado: (2000)

The orion complex a case study of interstellar matter
por: Goudis, C
Publicado: (1982)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews
por: Li, Jiayi, et al.
Publicado: (2023)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

ORION-VIRCAT: a tool for mapping ICTV and NCBI taxonomies
por: Valdivia-Granda, Willy, et al.
Publicado: (2009)

Orione, a web-based framework for NGS analysis in microbiology
por: Cuccuru, Gianmauro, et al.
Publicado: (2014)

Compression and ablation of the photo-irradiated molecular cloud the Orion Bar
por: Goicoechea, Javier R., et al.
Publicado: (2016)

Complete mitochondrial genome of the Greenland wolf, Canis lupus orion
por: Cho, Hyunjun, et al.
Publicado: (2019)

ORION software tool for the geometrical calibration of all-sky cameras
por: Antuña-Sánchez, Juan Carlos, et al.
Publicado: (2022)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022)

Clinical laboratory evaluation of the Orion SS-20 ionized calcium analyser
por: Ferreira, Patrick, et al.
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_vmhqboq4qlb8anv8mq86shu3j5